Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.88487
Peer-review started: September 26, 2023
First decision: November 23, 2023
Revised: November 23, 2023
Accepted: December 19, 2023
Article in press: December 19, 2023
Published online: March 25, 2024
Processing time: 167 Days and 2.3 Hours
Hepatitis B virus (HBV) reactivation poses a significant clinical challenge, espe
Core Tip: Reactivation of hepatitis B (HBV) induces a rapid and acute increase in viral replication in a patient with chronic HBV infection or prior HBV exposure. There is also an increased risk of HBV reactivation in patients treated with monoclonal antibodies. Organ damage can be due to various mechanisms and risk factors that activate the cascade of inflammatory responses, such as direct infection. It is of clinical importance to diagnose, manage, and treat individuals, especially those at risk. Patient outcomes, success of therapy, prevention of complications, and management of existing comorbidities depend on the correct multidisciplinary management in patients at risk.
- Citation: De Pauli S, Grando M, Miotti G, Zeppieri M. Hepatitis B virus reactivation in patients treated with monoclonal antibodies. World J Virol 2024; 13(1): 88487
- URL: https://www.wjgnet.com/2220-3249/full/v13/i1/88487.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i1.88487
Hepatitis B virus (HBV) infection can lead to acute or chronic infectious disease, particularly the latter when the infection is contracted during childhood. Chronic hepatitis B is estimated to affect 291 million people worldwide, of which almost 80% live in developing countries[1]. When the infection becomes chronic, the virus can remain in the organism in a latent form, thus acting as a reservoir for disease reactivation, which can also occur when there is evidence of recovery of the anti-HBV immune capacity (production of anti-HBs)[2].
When a patient is subjected to immunosuppressive therapy, HBV reactivation may occur. This condition is fairly common and can lead to serious consequences. Various treatments can induce viral reactivation, including oncological chemotherapies, checkpoint inhibitor therapies, stem cell treatments, immunobiological agents such as monoclonal antibodies (mAbs), etc[3]. The role of mAbs is fundamental in HBV reactivation.
HBV reactivation can be considered as sudden and high viral replication in a patient with chronic HBV infection or previous viral exposure[4]. The primary HBV infection can be considered resolved by the presence and development of anti-HBs antibodies. However, as previously mentioned, HBV can remain latent in the body, acting as a reservoir for disease reactivation[2]. HBV reactivation can present with various symptoms. There are mild forms of hepatitis but also severe ones, which can lead to acute liver failure and death.
Following the 2018 American Association for the Study of Liver Diseases guidelines[5], the state of HBV reactivation in hepatitis B surface antigen (HBsAg)-positive and anti-HBc-positive patients can be defined according to the following parameters: (1) At least 2 log (or 100-fold) increase in HBV DNA compared to the baseline level; (2) HBV DNA at least 3 log (or 1000) IU/mL in a patient with previously undetectable HBV DNA; and (3) HBV DNA at least 4 log (or 10000) IU/mL if the baseline level is not available.
For HBsAg-negative and anti-HBc-positive patients, HBV reactivation is defined as detectable HBV DNA or reap
The risk factors for HBV reactivation can be summarized into three general areas: (1) Host factors; (2) virologic factors; and (3) type and degree of immunosuppression[6]. Possible host risk factors include: The male sex, older age, presence of cirrhosis, and the type of disease needing immunosuppressive therapies[7]. Virologic factors include high baseline HBV DNA, HBeAg positivity, and chronic hepatitis B[8]. Referring to the risk factors related to immunosuppressive therapy, these depend above all on the type of underlying pathology and its involvement at a systemic level (e.g., hematologic disease). As already mentioned, a variety of treatments may induce HBV reactivation, such as immunosuppressive and chemotherapies which have the greatest risk of causing HBV reactivation. The American Gastroenterology Association (AGA) categorizes drugs based on their potential to cause HBV reactivation[9].
When the risk of causing HBV reactivation is greater than 10%, the drug can be defined as high risk. Among these drugs, there are B-cell-depleting agents, anthracycline derivatives, moderate-dose corticosteroid therapy (e.g., 10-20 mg prednisone daily), or high-dose corticosteroid therapy (e.g., > 20 mg prednisone daily). Drugs classified as having a moderate risk (between 1 and 10%) of reactivation include tumor necrosis factor (TNF)-α inhibitors, cytokine or integrin inhibitors, and tyrosine kinase inhibitors. Lastly, those considered at low risk of HBV reactivation (less than 1%) include immunosuppressive agents (e.g., azathioprine and methotrexate), and corticosteroid therapy[9].
In this mini-review, the risk of HBV reactivation in patients treated with mAbs is briefly discussed. In a recent review published in Antibodies[10], there is a warning of adverse liver reactions after the initiation of mAbs. Notably, among the mAbs at high risk of HBV reactivation are anti-CD20 agents; TNF-α inhibitors are instead considered by the authors to be moderate risk. The main results of the current literature are summarized in Table 1.
Ref. | Type of study | Conclusions |
Baldo et al[10], 2022 | Review | Warning of adverse liver reactions after the initiation of mAbs. mAbs that are at high risk of HBV reactivation, TNF-α inhibitors are at moderate risk |
Evens et al[13], 2011 | Meta-Analysis | 118 cases were reported to the US FDA in which rituximab was associated with HBV reactivation |
Dusheiko et al[14], 2023 | Review | B-cell–depleting therapy with rituximab highlights the contribution of memory B cells to HBV control |
Nathan et al[15], 2006 | Review | TNF inhibits hepatitis viral replication and stimulates HBV-specific T-cell responses to clear the virus from infected hepatocytes. TNF could cause increased expression of hepatitis B viral antigens |
Megna et al[16], 2022 | Prospective cohort study | Highlights the risk of HBV reactivation in patients with latent infection treated with secukinumab without prophylaxis |
Chiu et al[17], 2018 | Multicenter Study | Without antiviral prophylaxis, 7 of 46 (15.2%) patients with HBV exhibited viral reactivation during therapy with secukinumab |
Chiu et al[18], 2013 | Clinical Trial | Among 11 patients positive for hepatitis B surface antigen (HBsAg), two out of the seven (29%) patients who did not receive antiviral prophylaxis exhibited HBV reactivation |
Ting et al[19], 2018 | Prospective cohort study | Among the remaining 54 patients classified as inactive HBV carriers, resolved HBV infection, or isolated anti-HBc positivity, only 3 patients experienced virologic reactivation |
These drugs are widely used today. Rituximab and ofatumumab are humanized antibodies whose function is to bind to the CD20 receptor present on the surface of B lymphocytes, blocking their response and consequently humoral immunity[11,12]. Historically, rituximab has been the most studied drug in this category. The first work that highlighted the association between this drug and viral reactivation was reported by the FDA MedWatch Database[13] where 118 cases of reactivation were reported to occur between 1997 and 2009. Driven by this evidence, in 2013 the manufacturers of these drugs (rituximab and ofatumumab) were required to add label warnings that highlighted the high risk of possible virus reactivation[12]. These data highlight an interesting aspect: the risk of HBV reactivation linked to depletion of CD20+ B lymphocytes by rituximab highlights how important immunity is in controlling the disease itself[14].
Another highly used category of immunosuppressive drugs is anti-TNF alpha. They are widely used in treating rheumatological diseases such as rheumatoid arthritis and psoriasis, but also gastrointestinal diseases such as inflammatory bowel diseases. However, TNF is a fundamental element in countering HBV infection. Several studies have highlighted how it acts on two fronts: inhibiting virus replication and stimulating T cell immunity. The activated T-cells eliminate infected hepatocytes. Starting from this evidence, various authors have proposed that TNF inhibition through the above-men
Several studies demonstrate that other mAbs are at risk of HBV reactivation. Secukinumab is a fully human monoclonal antibody targeting interleukin-17A and is used for psoriatic disease. A recent retrospective study by Megna et al[16] highlights how HBV reactivation is possible in patients undergoing treatment with Secukinumab without prophylaxis. Another multi-center prospective cohort study by Chiu et al[17] (63 patients involved with concurrent HBV/hepatitis C virus infection) showed that, without antiviral prophylaxis, 15.2% of HBV patients treated with secukinumab exhibited viral reactivation[17]. Considering the data reported in the literature and the evidence cited above, it appears possible, albeit in very limited cases, that B and C viruses can be reactivated in cases of therapy with these molecules without antiviral prophylaxis[16].
Another drug studied for its relation to cases of HBV reactivation is Ustekinumab. It is a human interleukin-12 (IL-12) and IL-23 antagonist used in adult patients affected by plaque psoriasis, active psoriatic arthritis, and moderate-to-severe active Crohn’s disease where other therapies have failed (or in case of patients’ intolerance). Several studies have reported cases of HBV reactivation in HBsAg-positive patients treated with ustekinumab[18,19].
The current approach, according to the indications of the most recent guidelines, suggests that all patients undergoing treatment with drugs at high and moderate risk of HBV reactivation should be subjected to screening (serum evaluation of HBsAg, anti-HBc, and anti-HBs)[6]. For a more complete screening, blood levels of HBeAg, HBV DNA, and amino
Treatments with nucleoside analogue drugs such as entecavir or tenofovir are recommended in cases of chronic infection complicated by cirrhosis associated with the presence of HBV DNA in the blood[14]. Lamivudine can also be used in these cases but is burdened by high rates of drug resistance. For this reason, the use of entecavir and tenofovir should be preferred in cases where therapy with lamivudine has already been carried out, and tenofovir is to be preferred to entecavir, as explained by Ekpanyapong et al[21].
It is good practice to test all patients before starting immunosuppressive treatments. If serological HBV positivity is found, patients at high reactivation risk should undergo prophylactic treatment with anti-HBV nucleoside analogues. This approach saw the greatest chance of preventing viral reactivation[4]. For example, the American Gastroenterological Association recommends prophylaxis for patients undergoing high-risk and moderate-risk immunosuppressive therapy. This prophylactic treatment should be continued for at least 6 mo after the end of immunosuppressive therapy (12 mo if B-cell-depleting agents were used)[9].
There are currently several prophylaxis protocols studied and available. The most frequently used drugs are lamivudine, entecavir, adefovir, tenofovir disoproxil fumarate, and tenofovir alafenamide. All have demonstrated usefulness in preventing HBV reactivation, but entecavir has demonstrated the greatest efficacy in prophylactic treatment[4].
Future and ongoing research on HBV reactivation must evaluate the complexity of this illness. The risk of HBV reactivation can be associated with immunosuppressive therapy and reactivation. These drugs include those used to treat autoimmune illnesses, organ transplants, and specific types of cancer. Research should examine how these treatments impact the host immune system and help latent HBV reactivate. Molecular processes and viral components may also significantly contribute. One of the main areas of research is understanding the molecular processes of HBV reactivation. This entails investigating how the virus endures in the liver and how certain circumstances can cause reactivation.
Innovative studies might concentrate on factors related to viruses, including modifications in viral gene expression, mutations, or adjustments in the viral life cycle that support reactivation. Genetic predisposition and host variables may also be significant. Studies may look at host variables that make people more vulnerable to HBV reactivation. This includes genetic variants that could impact the virus's ability to withstand immunological responses or maintain viral latency. Predicting which individuals are more likely to experience reactivation can be aided by identifying particular host variables. Antiviral prophylaxis, timing of therapies, and monitoring techniques are all part of clinical care and prevention. There is also ongoing research on the creation and assessment of preventive interventions such as immunization and antiviral medications.
HBV reactivation is a potentially fatal complication after immunosuppressive biological or targeted therapy. Despite monoclonal antibodies having target specificity, they are not free of adverse effects, including HBV reactivation. Reports from the literature demonstrate that this is more frequent in patients treated with anti-CD20 or anti-TNF. However, there are some case reports of other mAbs causing this adverse event. Many unanswered questions remain about the risk of HBV reactivation associated with recently introduced mAbs. These questions provide an opportunity for monitoring and research.
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Virology
Country/Territory of origin: Italy
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C, C
Grade D (Fair): D
Grade E (Poor): 0
P-Reviewer: Mucenic M, Brazil; Fan YC, China; Gao S, China; Kelleni MT, Egypt S-Editor: Liu JH L-Editor: Filipodia P-Editor: Zhang YL
1. | GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7:796-829. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 263] [Cited by in F6Publishing: 285] [Article Influence: 142.5] [Reference Citation Analysis (0)] |
2. | Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104-1108. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 624] [Cited by in F6Publishing: 588] [Article Influence: 21.0] [Reference Citation Analysis (1)] |
3. | Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77:1670-1689. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis (0)] |
4. | Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. Hepatitis B virus reactivation: Risk factors and current management strategies. Pharmacotherapy. 2019;. [DOI] [Cited in This Article: ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis (0)] |
5. | Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2290] [Cited by in F6Publishing: 2562] [Article Influence: 427.0] [Reference Citation Analysis (0)] |
6. | Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 426] [Cited by in F6Publishing: 409] [Article Influence: 58.4] [Reference Citation Analysis (0)] |
7. | Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299-307. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 12] [Reference Citation Analysis (0)] |
8. | Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209-220. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 358] [Cited by in F6Publishing: 363] [Article Influence: 20.2] [Reference Citation Analysis (0)] |
9. | Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215-9; quiz e16. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 414] [Cited by in F6Publishing: 408] [Article Influence: 45.3] [Reference Citation Analysis (0)] |
10. | Baldo BA. Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies (Basel). 2022;11. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis (0)] |
11. | Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605-611. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 486] [Cited by in F6Publishing: 476] [Article Influence: 31.7] [Reference Citation Analysis (0)] |
12. | Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310:1664. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
13. | Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170-1180. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 241] [Cited by in F6Publishing: 260] [Article Influence: 18.6] [Reference Citation Analysis (0)] |
14. | Dusheiko G, Agarwal K, Maini MK. New Approaches to Chronic Hepatitis B. N Engl J Med. 2023;388:55-69. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 36] [Cited by in F6Publishing: 54] [Article Influence: 54.0] [Reference Citation Analysis (0)] |
15. | Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21:1366-1371. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 106] [Cited by in F6Publishing: 113] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
16. | Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Romita P, Raimondo A, Loconsole F, Fabbrocini G. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Clin Drug Investig. 2022;42:525-531. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
17. | Chiu HY, Hui RC, Huang YH, Huang RY, Chen KL, Tsai YC, Lai PJ, Wang TS, Tsai TF. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018;98:829-834. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis (0)] |
18. | Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295-1303. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 10.7] [Reference Citation Analysis (0)] |
19. | Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis (0)] |
20. | European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3745] [Cited by in F6Publishing: 3469] [Article Influence: 495.6] [Reference Citation Analysis (0)] |
21. | Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-333. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis (0)] |